» Articles » PMID: 26844505

Efficacy and Safety of Bisphosphonates for Low Bone Mineral Density After Kidney Transplantation: A Meta-Analysis

Overview
Specialty General Medicine
Date 2016 Feb 5
PMID 26844505
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

In patients with low bone mineral density (BMD) after kidney transplantation, the role of bisphosphonates remains unclear. We performed a systematic review and meta-analysis to investigate the efficacy and safety of bisphosphonates.We retrieved trials from PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL) from inception through May 2015. Only randomized controlled trials that compared bisphosphonate-treated and control groups of patients with low bone mineral density after kidney transplantation were included. The primary outcomes were the percent change in BMD, the absolute change in BMD, and the BMD at the end of study at the lumbar spine. The results were expressed as the mean difference (MD) or relative risk (RR) with the 95% confidence interval (CI). We used a random-effects model to pool the outcomes.We included 17 randomized controlled trials with 1067 patients. Only 1 included trial was found to be at low risk of bias. The rest of the included studies were found to have high to uncertain risk of bias. Compared with the control group, those who received bisphosphonates had a significant increase in percent change in BMD (mean difference [MD] = 5.51, 95% confidence interval [CI] 3.22-7.79, P < 0.00001) and absolute change in BMD (MD = 0.05, 95% CI 0.04-0.05, P < 0.00001), but a nonsignificant increase in BMD at the end of the study (MD = 0.02, 95% CI -0.01 to 0.05, P = 0.25) at the lumbar spine. Bisphosphonates resulted in a significant improvement in percent change in BMD (MD = 4.95, 95% CI 2.57-7.33, P < 0.0001), but a nonsignificant improvement in absolute change in BMD (MD = 0.03, 95% CI -0.00 to 0.06, P = 0.07) and BMD at the end of the study (MD = -0.01, 95% CI -0.04 to 0.02, P = 0.40) at the femoral neck. No significant differences were found in vertebral fractures, nonvertebral fractures, adverse events, and gastrointestinal adverse events.Bisphosphonates appear to have a beneficial effect on BMD at the lumbar spine and do not significantly decrease fracture events in recipients. However, the results should be interpreted cautiously due to the lack of robustness and the heterogeneity among studies.

Citing Articles

Evaluation of Bone Mineral Density in Lung Transplant Recipients by Chest Computed Tomography.

Mori R, Handa T, Ohsumi A, Ikezoe K, Tanizawa K, Uozumi R Respiration. 2023; 103(1):1-9.

PMID: 38052185 PMC: 10823555. DOI: 10.1159/000535269.


Efficacy of iguratimod on mineral and bone disorders after kidney transplantation: a preliminary study.

Sun L, Tao J, Han Z, Chen H, Huang Z, Wang Z Ren Fail. 2023; 45(2):2256418.

PMID: 37905940 PMC: 11001337. DOI: 10.1080/0886022X.2023.2256418.


Efficacy of Osteoporosis Medications for Patients With Chronic Kidney Disease: An Updated Systematic Review and Network Meta-Analysis.

Chen C, Lo W, Hu P, Chan H, Shen W, Wu M Front Pharmacol. 2022; 13:822178.

PMID: 35222037 PMC: 8873386. DOI: 10.3389/fphar.2022.822178.


Risk Factors and Management of Osteoporosis Post-Transplant.

Kovvuru K, Kanduri S, Vaitla P, Marathi R, Gosi S, Garcia Anton D Medicina (Kaunas). 2020; 56(6).

PMID: 32575603 PMC: 7353876. DOI: 10.3390/medicina56060302.


Effect of Bisphosphonates on Bone Health in Adult Renal Transplant Patients: Beyond the First Year Posttransplant-A Systematic Review and Meta-Analysis.

Lip A, Warias A, Shamseddin M, Thomson B, Wijeratne D Can J Kidney Health Dis. 2019; 6:2054358119858014.

PMID: 31263566 PMC: 6595663. DOI: 10.1177/2054358119858014.


References
1.
DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

2.
Adachi J, Bensen W, Brown J, Hanley D, Hodsman A, Josse R . Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med. 1997; 337(6):382-7. DOI: 10.1056/NEJM199708073370603. View

3.
Walsh S, Altmann P, Pattison J, Wilkie M, Yaqoob M, Dudley C . Effect of pamidronate on bone loss after kidney transplantation: a randomized trial. Am J Kidney Dis. 2009; 53(5):856-65. DOI: 10.1053/j.ajkd.2008.11.036. View

4.
Nayak B, Guleria S, Varma M, Tandon N, Aggarwal S, Bhowmick D . Effect of bisphosphonates on bone mineral density after renal transplantation as assessed by bone mineral densitometry. Transplant Proc. 2007; 39(3):750-2. DOI: 10.1016/j.transproceed.2007.01.065. View

5.
Grotz W, Mundinger F, Gugel B, Exner V, Kirste G, Schollmeyer P . Bone fracture and osteodensitometry with dual energy X-ray absorptiometry in kidney transplant recipients. Transplantation. 1994; 58(8):912-5. DOI: 10.1097/00007890-199410270-00009. View